Not seeing results with Semaglutide
According to the company's FAQ, FDA-approved GLP-1/GIP medications including Ozempic, Wegovy, Zepbound, and Mounjaro "may also be eligible for coverage," and the company states it assists with prior authorizations and prescription submissions for these medications
More specifically, data showed that semaglutide decreased the overall likelihood of the following, regardless of the severity of diabetes-related kidney disease: Either serious heart failure for the first time or cardiovascular death, by 27% Heart failure events, by 27% Cardiovascular death, by 29% Positive effects were consistent, regardless of history of heart failure
Record injection dates, doses, side effects, and body composition metrics
Some women feel full faster or experience nausea with drinks they previously tolerated well
About This Weight Management Therapy and GLP-1 Agonists